logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q2 2021
ABIVAX SA
ABVX.PA
Top-line data from phase IIa clinical trial of ABX464 (ABX464-301)
Moderate to severe active rheumatoid arthritis
Q2 2021
Frequency therapeutics
Top-line data from Phase 2a clinical trial of FX-322
Sensorineural hearing loss or SNHL
Q2 2021
Celldex Therapeutics Inc.
Full results from Phase 1b study of CDX-0159
Chronic spontaneous urticaria (CSU)
Q2 2021
Novan Inc.
Top-line efficacy results from phase 3 trial of SB206 (B-SIMPLE4)
Molluscum
Q2 2021
AzurRx BioPharma, Inc.
Topline data from phase 2 combination therapy trial of MS1819 with PERT therapy
Cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI)
Q2 2021
Enanta Pharmaceuticals Inc.
Preliminary data from Phase 1b study of core Inhibitor EDP-514
NUC-suppressed Hepatitis B (HBV) patients
Q2 2021
Enanta Pharmaceuticals Inc.
Data from phase 1 study of EDP-297
Non-Alcoholic Steatohepatitis (NASH)
Q2 2021
Entera Bio Ltd.
Final Biomarker Data from 2.5 mg Dose in Phase 2 Study of EB613
Osteoporosis
Q2 2021
Fulcrum Therapeutics
Full data from phase II clinical trial of Losmapimod to include analyses of DUX4 gene signature and MRI(ReDUX4)
Facioscapulohumeral muscular dystrophy
Q2 2021
Kintara Therapeutics, Inc
Topline results from Phase 2 Study of VAL-083
MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Q2 2021
Aileron Therapeutics, Inc.
Data Readout from Phase 1b Clinical Trial of ALRN-6924
Healthy Volunteer Study
Feb 2021
BioNTech
Completion of phase Ib trial of NEO-PV-01 and Keytruda
Advanced or metastatic nonsquamous non-small cell lung carcinoma
15-Jan-2021
Arcus Biosciences, Inc
Updated data from phase I portion of phase I/Ib study of AB680 in combination with Zimberelimab and nab-paclitaxel plus gemcitabine
Front-line metastatic pancreatic cancer
Q1 2021
IMARA Inc.
Updates from phase IIa open label extension trial of IMR-687
Sickle cell disease
Q1 2021
Lineage Cell Therapeutics, Inc.
New and accumulated data from Phase 1/2a trial of OpRegen
Dry age-related macular degeneration with geographic atrophy
Q1 2021
Idera Pharmaceuticals, Inc.
Topline data from phase 3 trial of tilsotolimod in combination with ipilimumab versus ipilimumab (ILLUMINATE-301)
Anti-PD-1 Refractory Advanced Melanoma
2021
InflaRx N.V.
Results from phase IIa open label trial of IFX-1
Pyoderma Gangraenosum (PG)
2021
Incyte Corporation
Results from Phase III trial of ruxolitinib cream (TRuE-V2)
Vitiligo
2021
Incyte Corporation
Results from Phase III trial of ruxolitinib cream (TRuE-V1)
Vitiligo
after Q1 2021
Inhibrx, Inc.
Initial dose escalation data from phase I trial of INBRX-105(PDL1x41BB)
Solid tumors
Q1 2021
IMV Inc.
Updated results from Phase II study of DPX-Survivac/CPA in combination with Keytruda across five cohorts of patients (Basket Trial)
Bladder cancer, liver cancer, ovarian cancer, NSCLC and tumors
Q1 2021
Kintara Therapeutics, Inc
Topline results from Phase 2 Study of VAL-083
Recurrent malignant glioma
Q1 2021
Immunic, Inc
Full data readout from phase II study of IMU-838 (CALDOSE-1)
Ulcerative colitis
Early 2021
Savara Inc
Top line results from phase III trial of AeroVanc (AVAIL)
Persistent methicillin-resistant Staphylococcus aureus
2021
AIM ImmunoTech Inc.
Data from phase II clinical study combining Ampligen, cisplatin and pembrolizumab
Ovarian cancer